GIC explains how it is tapping China opportunities

Asset Owners

Indira Vergis

Nov 6, 2018

With its eyes on the long-term prize, the Singaporean sovereign wealth fund continues to sharpen its investment interest in Chinese assets.

For most of the region’s asset owners that can invest beyond their borders, investing China is unavoidable.

GIC is no exception as Singapore’s sovereign...

0 0 0 0 0

Just Published

Asset Owners

11 hours ago

Jolie Ho

The group CIO of the third-largest insurer in China discusses how the lifer is going to lengthen asset duration and possibly increase overseas exposure.

Asset Owners

11 hours ago

Jaycee Man

China Pacific Insurance's CIO and other market specialists share their views on how US monetary policy could play out in coming months, and what that could mean for investments.

Asset Owners

11 hours ago

Richard Newell

With public markets set to face a challenging 2019, institutional investors will need to stay diversified to protect portfolios. A dynamic approach that blends different styles of investing can help.

GIC explains how it is tapping China opportunities

Follow Us

Most Read

Eastspring’s C-suite shakeup fuels sell-off talk

BNP Paribas AM hires from Conning for quant buildout

Weekly roundup of people news, Feb 15

Zurich’s HK, Singapore units to enter private debt

Alternatives giant Ares raids UBS for Asia push

EPF plans to raise property and infra exposure

Singapore Life set to add managers, expand regionally

MPF urged to allow A-share, HK fund, Reit investments

CPIC Life to raise its exposure to private equity

Zurich strives to cut HK portfolio duration gap

Related Articles

Insto roundup: New China insurer rules; GIC adds to board

Insto news roundup: Kwap in revamp, GIC creates China fund

GIC sees challenges for value investing

Insto roundup: BLF shortlists managers; Korea Post’s infra RFPs

Just Published

How CPIC Life seeks to close duration gap

Market Views: Where next for US interest rates?

Asset owners need ‘multi-faceted’ approach to risk

Next-gen sequencing: Why gene research delivers returns to investors